| Objective:This topic using the method of the combination of clinical and experimental research,to observe the effect of liu-shen-wan in treating the post-operative patients, and the expressive of integrin beta 1 and epithelial cadherins about high transfer people with lung adenocarcinoma A549 cells . Methods: Clinical research part into 45 patients with cancer patients were randomly divided into trial group (chemotherapy/EP or NP plan + liu-shen-wan) and the control group (chemotherapy group/EP or NP scheme), the observation group 24 cases and control 21 cases.The patients in the two groups were treated 4-treatment. After the treatment, compared the two groups with the recent ratings, KaShi objective curative effect, weight, immune function changes and the reaction and toxicity of the appearance. In the experimental research part, the method of serum pharmacology was used. MTT is used to set out the cytotoxic and growth inhibition of the serum which containing liu-shen-wan. Immunohistochemical method determination of Integrin beta 1 and Epithelial cadherins (E - cd) expression changes and to compare with liu-shen-wan, the mechanism of action of resistance to transfer will be further discussed. Results: Clinical research proved, the observation group can reduce the recurrence of cancer metastasis rate and improve the quality of life of the patients, stabilize and gain weight, improve the immune function, effectively reduce the adverse reaction of chemotherapy. Experimental study confirms the serum containing liu-shen-wan may restrain Integrin beta 1 and E-cd expression, and share synergistic effect with cisplatin. Conclusion: The treatment of Liu-shen-wan combinating chemotherapy for lung cancer has an obvious efficacy. It can reduced poison effectly, and also can significantly reduce the recurrence and shift rate of lung cancer patients. |
PDF Full Text Request